Keisuke Aoe
Ube, 7550241, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 05, 2023
Health Care Resource Use Among Patients with Advanced Non-Small Cell Lung Cancer in Japan, 2017-2019.
Journal: Current therapeutic research, clinical and experimental
Published: February 07, 2023
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Journal: Journal for immunotherapy of cancer
Published: October 07, 2021
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.
Journal: Japanese journal of clinical oncology
Published: March 29, 2021
Malignant pleural mesothelioma with heterologous elements.
Journal: Journal of clinical pathology
Published: March 25, 2021
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Journal: Cancer medicine
Published: December 08, 2020
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma.
Journal: JTO clinical and research reports
Published: December 07, 2020
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Journal: Therapeutic advances in medical oncology
Published: November 10, 2020
Last Updated: 09/26/2026